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Abstract
 
High risk human papillomaviruses (HPVs) are central to the development of cervical cancer
and the deregulated expression of high risk HPV oncogenes is a critical event in this process.
Here, we find that the cell protein nucleolin binds in a sequence-specific manner to the
HPV18 enhancer. The DNA binding activity of nucleolin is primarily S phase specific, much
like the transcription of the E6 and E7 oncoproteins of HPV18 in cervical cancer cells. Anti-
sense inactivation of nucleolin blocks E6 and E7 oncogene transcription and selectively de-
creases HPV18
 
 
 
cervical cancer cell growth. Furthermore, nucleolin controls the chromatin
structure of the HPV18 enhancer. In contrast, HPV16 oncogene transcription and proliferation
rates of HPV16
 
 
 
SiHa cervical cancer cells are independent of nucleolin activity. Moreover,
nucleolin expression is altered in HPV18
 
 
 
precancerous and cancerous tissue from the cervix
uteri. Whereas nucleolin was homogeneously distributed in the nuclei of normal epithelial
cells, it showed a speckled nuclear phenotype in HPV18
 

 
 
 
carcinomas. Thus, the host cell pro-
tein nucleolin is directly linked to HPV18-induced cervical carcinogenesis.
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Introduction
 
High risk human papillomaviruses (HPVs)
 
* 
 
play a central
etiologic role in the development of cervical cancer (1),
which represents the second most common malignancy in
women with an annual incidence of 
 

 
500,000 new cases
(2). A recent report demonstrated that 99.7% of all cervical
cancers contain high risk HPV types (3). Of the oncogenic
HPV types, HPV16 and HPV18 are found with the highest
frequency in invasive cervical carcinomas in most popula-
tions (3). In adenocarcinomas, however, HPV18 is the
most prevalent type (4). Accumulating clinical and experi-
mental research suggests that HPV18 infection is associated
with a more aggressive form of cervical neoplasia than
HPV16 infection (5–8) and it has been shown by a cell
transformation assay that its upstream regulatory region
(URR) has a 10–50-fold higher transforming activity than
HPV16 (9). Papillomaviruses initially infect the basal cell
layer of the cervical squamous epithelium and persist as a
latent infection (for review see reference 10). In high grade
squamous intraepithelial lesions (HSILs), squamous cell car-
cinomas and adenocarcinomas, the HPV genomes are
usually integrated into the host cell genome and the E6 and
E7 oncogenes are highly expressed (11, 12). Most recently
it was reported that within the host cell genome no prefer-
ential integration sites for HPV18 and HPV16 genomes
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could be identified (13). These results indicate that target-
directed insertional mutagenesis or the activation of nearby
oncogenes apparently plays a minor role for the develop-
ment of HPV-associated cervical cancers. In contrast, the
E6 and E7 oncoproteins exert their carcinogenic potential
by inactivation of the tumor suppressors pRB and p53 (14–
16). The papillomavirus oncogenes cause progressive squa-
mous intraepithelial neoplasias (17). Thus, deregulated high
risk HPV oncogene expression is a critical event in papillo-
mavirus-associated carcinoma development. Therefore, it is
essential to work out the mechanisms of HPV oncogene
expression to understand cervical cancer development at a
molecular level. The HPV18 enhancer (18) has been stud-
ied extensively by DNase I footprinting, site directed mu-
tagenesis, and transient reporter gene assays, and it was
shown that in cervical carcinoma cells E6/E7 oncogene ex-
pression is dependent not on viral, but on cellular transcrip-
tion regulators (19–26). It is, however, not completely un-
derstood how HPV18 oncogene expression is controlled in
the process of human squamous cell carcinoma and adeno-
carcinoma development. Here, we report a previously un-
recognized involvement of the cellular protein nucleolin in
HPV18-associated cervical carcinogenesis. Nucleolin is a
phosphoprotein whose synthesis positively correlates with
cell division rates (27). Nucleolin is a multifunctional pro-
tein and is a downstream target of several signal transduc-
tion pathways (for review see references 28 and 29). For
example, fibroblast growth factor 2 stimulates the activity
of CK2 toward nucleolin (30), nucleolin phosphorylation is
controlled by androgens (31), and nucleolin expression is
activated by IL-2 in T cells (32). Here, we show that nu-
cleolin is a key activator of HPV18 oncogene transcription
involved in chromatin structure regulation and we demon-
strate that nucleolin is not only expressed in HPV18
 
 
 
squa-
mous cell carcinomas and adenocarcinomas of the cervix
uteri, but also shows an abnormal intranuclear localization
compared with normal cervical epithelial cells. Thus, we
have identified nucleolin as a cellular protein with onco-
genic potential.
 
Materials and Methods
 
Preparation of Nuclear Extracts, Protein Purification, and Sequenc-
ing.
 
HeLa cells were purchased from the 4C Biotech and
nuclear extracts were prepared as previously described (33). Pro-
tein purification on DNA affinity columns was performed ac-
cording to a published protocol (34). In brief, nuclear extracts
were loaded onto heparin-Sepharose in a buffer containing 20
mM Tris, pH 8.0, 60 mM NaCl, 1 mM EDTA, 1 mM 1,4-
dithio-DL-threitol, 5% glycerol, and protease inhibitors. The
fraction eluted from the column with loading buffer containing
500 mM NaCl was dialyzed and applied to a DNA affinity col-
umn, which was prepared by coupling the double stranded en-
hancer fragment corresponding to nucleotide numbers 7634–
7671 (35), termed here RP3, to CNBr-activated Sepharose.
Proteins eluted from the RP3 oligonucleotide DNA affinity col-
umn with 500 mM NaCl were analyzed by SDS-PAGE. The fi-
nal protein preparation was apparently homogeneous, as judged
by 2D electrophoresis. Internal peptides were generated from
 
the corresponding gel band by in situ digestion with trypsin (36)
and peptides were separated on a reverse phase column using a
SMART System (Amersham Biosciences). Alternatively, the
protein was transferred to a high retention polyvinylidene diflu-
oride membrane (Bio-Rad Laboratories) using 10 mM Caps
buffer, pH 11.0, containing 10% methanol (v/v), 0.07% SDS,
for 2.5 h at 1 mA/cm
 
2 
 
and the blotted protein and selected frac-
tions from the HPLC run of internal peptides were subjected to
 
N
 
-terminal Edman microsequencing using the Procise
 
® 
 
se-
quencer (Applied Biosystems).
 
Generation of Polyclonal Nucleolin Peptide Antibodies.
 
A conju-
gate of the NH
 
2
 
-terminal peptide of nucleolin, VKLAKAGKN-
QGDPKKM, coupled to KLH was used to generate a polyclonal
rabbit Ab specific for nucleolin. The Ab was affinity purified on a
peptide column according to standard protocols. Affinity-purified
Ab specific for nucleolin was used throughout this study.
 
Cell Culture and Synchronization.
 
Hela cells, HeLa-fibroblast
hybrid cell line 444 (37), SW756 cells (38), SiHa cells, and
HaCaT and SiHa 
 
 
 
HaCaT hybrids (39) were maintained in
DME supplemented with 10% FCS. Detailed cell synchroniza-
tion conditions and the necessary controls have been described
(33). In brief, G1 phase cells were prepared by 20 
 

 
M lovastatin
treatment for 24 h, S phase cells by 3 
 

 
M aphidicolin treatment
for 24 h followed by a 2-h release in fresh medium, and G2 phase
cells by 3 
 

 
M aphidicolin treatment for 24 h followed by a 6-h
release in fresh medium. Mitotic cells were prepared by 10 
 

 
g/ml
nocodazole treatment for 18 h and thereafter the shake-off cells
were collected. G0 phase cells were prepared by a 48-h cultiva-
tion in serum-free medium. Synchronization efficiencies were
monitored by FACS
 
® 
 
analysis. In addition, S phase synchroniza-
tion was controlled by the detection of histone H3 mRNA, and
G2 phase synchronization was monitored by immunoblotting
with a cyclin B1 Ab. To assess G0 synchronization, the expres-
sion of Ki67-Ag was determined by immunoblot analysis.
 
Antisense Inhibition of Nucleolin Expression and Proliferation As-
says.
 
The nucleolin phosphorothioate-antisense oligonucle-
otide 5
 

 
-TCACCATGATGGCGGCGG-3
 
 
 
is complementary
to the 5
 
 
 
end of the mRNA of human nucleolin encompassing
the translation initiation region. For antisense inhibition experi-
ments, phosphorothioate-modified oligonucleotides were added
in concentrations indicated in the figure legends. After 60 h, the
cells were harvested and used for the preparation of nuclei, nu-
clear extracts, and RNA. Proliferation assays were performed us-
ing the bromodeoxuridine (BrdUrd) proliferation ELISA kit
(Roche Diagnostics). Nucleolin antisense inhibition in prolifera-
tion assays was performed using 1 
 

 
M phosphorothioate-modi-
fied antisense and sense oligonucleotides, and oligonucleotides
were applied to growing cells using DOTAP reagent (Roche Di-
agnostics) to enhance transfection efficiency. After an initial in-
cubation for 15 h, the culture medium was changed, and the cells
were incubated for an additional 48 h. BrdUrd was added for 9 h
and the BrdUrd incorporation was determined as described in
the manufacturer’s protocol.
 
Electrophoretic Mobility Shift Assay (EMSA), Immunoshift, and Im-
munoblot Analysis.
 
The conditions for DNA binding and EMSA
have been described (33). For immunoshift assays, nuclear protein
extracts were preincubated with the nucleolin Ab for 30 min be-
fore processing the reactions for EMSA. As specificity control,
the Ab specific for nucleolin was presaturated with the immuniz-
ing nucleolin peptide for 15 min at room temperature.
The glutathione 
 
S
 
-transferase (GST)–nucleolin fusion protein
was generated by cloning the cDNA fragment corresponding to
amino acid residues 289–709 of the nucleolin cDNA (40) in
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frame with GST cDNA into vector pGEX2T. The fusion protein
was produced in 
 
Escherichia coli
 
 and purified by affinity chroma-
tography using glutathione-Sepharose (Amersham Biosciences) as
described in the manufacturer’s protocol. To detect DNA bind-
ing, 50 ng purified GST–nucleolin protein or GST protein was
incubated with 50 ng poly (dIdC)(dIdC) and labeled, double
stranded RP3 or AP1 oligonucleotides for 15 min at room tem-
perature, and analyzed by EMSA.
Immunoblot analysis was performed according to standard
procedures. The following are antibodies and their dilutions: Ab
specific for nucleolin, 1:10,000; Ab specific for Sp1 (PEP2; Santa
Cruz Biotechnology, Inc.), 1:2,000; mAb specific for proliferat-
ing cell nuclear antigen (PCNA; Santa Cruz Biotechnology,
Inc.), 1:2,000; Ab specific for Cdk4 (provided by M. Pagano,
New York University School of Medicine, New York, NY),
1:2,000; and mAb specific for 
 
 
 
actin (Sigma-Aldrich), 1:2,000.
 
Preparation of RNA and Northern Blot Analysis.
 
The prepara-
tion of total cellular RNA and Northern blot analysis was per-
formed according to previously published procedures (41, 42)
with minor modifications. For the preparation of nuclear RNA,
the cells were first lysed with a buffer containing 140 mM NaCl,
1.5 mM MgCl
 
2
 
, 10 mM Tris-HCl, pH 8.0, 0.5% NP-40, 1 mM
1,4-dithio-DL-threitol. Subsequently, nuclei were collected by
low speed centrifugation and RNA was isolated according to the
protocol described above. For Northern blot analysis of HPV18
mRNA, total or nuclear RNA (5 
 

 
g) was fractionated on 1.2%
agarose-formaldehyde gels, transferred to charged nylon mem-
branes (Zeta-Probe; Bio-Rad Laboratories), and hybridized over-
night at 47
 

 
C in the presence of 50% formamide. HPV18 DNA
probes were radioactively labeled to a specific activity of 10
 
7
 
cpm/50 ng DNA using a nick translation kit (Roche Diagnos-
tics). For the detection of HPV16 mRNA in SiHa and SiHa 
 

 
HaCaT hybrid cells by Northern hybridization, we used a
HPV16 unit length DNA (provided by M. Dürst, University of
Jena, Jena, Germany; reference 43). Here, we used 0.5 
 

 
g poly
A–selected RNA per sample and RNA was separated on a 1%
agarose gel in the presence of ethidium bromide under nondena-
turing conditions (44) and transferred to GeneScreen Plus mem-
branes (NEN Life Science Products). The filter was hybridized
under stringent conditions with specific probes labeled with
[
 
32
 
P]dCTP by random priming (45).
 
Transient Transfections and Chloramphenicol Acetyltransferase Re-
porter Gene (CAT) Assays.
 
We have reported the creation of an
HPV16
 
 
 
cervical carcinoma cell line (SiHa), where contiguous
HPV18 URR fused to the CAT is stably integrated, and HaCaT
hybrid cells thereof (39). To determine the activity of the inte-
grated HPV18 URR-CAT construct in SiHa and SiHa 
 

 
HaCaT hybrid cells we used a CAT ELISA kit (Roche Diagnos-
tics). The results obtained by CAT ELISA were normalized to
protein concentration according to the manufacturer’s specifica-
tions. For transient transfections, a cytomegalovirus promoter-
driven nucleolin expression construct was used (46). The DNA
was purified using a plasmid purification system (QIAGEN) and
cells were transiently transfected according to standard proce-
dures. HPV18 URR-CAT activity in transiently transfected cells
was measured by a CAT-ELISA kit (Roche Diagnostics).
 
Detection of a DNase I Hypersensitive (HS) Site in the HPV18 En-
hancer.
 
For the detection of the DNase I HS site in the HPV18
enhancer chromatin, we followed our published procedure (47).
In brief, cells were lysed with 0.6% NP-40 and the nuclei were
washed twice with isotonic Tris buffer and resuspended in DNase
I digestion buffer (10 mM Tris-HCl, pH 7.5, 30 mM NaCl, 3
mM MgCl
 
2
 
). The nuclear DNA concentration was determined
and adjusted to 1 mg/ml, and then nuclei were digested with
DNase I (Roche Diagnostics) for 10 min at 37
 

 
C. The concen-
trations of DNase I are indicated in the figure legends. The reac-
tions were terminated by the addition of an equal volume of a
stop mixture containing 2% SDS and 40 mM EDTA. After pro-
teinase K digestion (50 
 

 
g/ml for 2 h at 37
 

 
C), the DNA was
phenol extracted, ethanol precipitated, and dissolved in 1
 
 
 
Tris-
EDTA buffer. DNA was then digested with EcoR I (30 U EcoR
I/5 
 

 
g DNA) for 5 h at 37
 

 
C, treated with 10 
 

 
g/ml RNase A,
and size fractionated in 0.8% agarose gels. After the transfer to
Zeta-Probe membranes (Bio-Rad Laboratories), the filters were
hybridized overnight at 47
 

 
C in the presence of 50% formamide
according to the manufacturer’s specifications. A DNA fragment
corresponding to the open reading frames of the E6-E7 onco-
genes of HPV18 was used as a probe for indirect end labeling of
the HPV18-containing EcoR I fragment on the Southern blot
(47). The DNA probe was labeled to a specific activity of 10
 
7
 
cpm/50 ng DNA using a nick translation kit (Roche Diagnostics)
and [
 
32
 
P]-labeled dNTPs.
 
Immunohistochemistry and Detection of HPV18 by PCR.
 
Paraf-
fin sections of human cervix specimens were immunostained
with the Ab specific for nucleolin after microwave treatment. For
immunohistochemistry, the polyclonal Ab specific for nucleolin
was used at a dilution of 1:200. As second Ab, a swine anti–rabbit
IgG was used at a 1:300 dilution. Specimens were then incubated
with an avidin biotin complex at a 1:200 dilution and then devel-
oped by an incubation with 3,3
 
 
 
diaminobenzidine tetrachloride
for 3 min and stained with hematoxylin for 30 s. For HPV detec-
tion, DNA was prepared from formalin-fixed, paraffin-embedded
tissue by standard procedures. HPV DNA was detected by
GP5
 

 
/6
 
 
 
PCR enzyme immunoassay and typing was per-
formed by reverse line blot hybridization according to our pub-
lished protocol (48).
 
Results
 
Nucleolin is an S Phase–specific HPV18 Enhancer Binding
Protein.
 
To gain insight into the control of HPV18 onco-
gene transcription, we analyzed whether this process
would be subject to cell cycle–dependent regulation. 444
cells were biochemically synchronized according to cell
cycle stage and HPV18 oncogene transcription was mea-
sured by Northern blot analysis using nuclear RNA. Cell
cycle synchronization efficiencies were controlled as previ-
ously described (33). E6/E7 oncogene transcription was
just detectable in G
 
1
 
, G
 
2
 
, and M phase, however, HPV18
oncogenes were strongly transcribed in S phase (Fig. 1 A,
top). To monitor S phase synchronization, histone H3
mRNA was detected (Fig. 1 A, bottom). Similar results
were obtained using cells synchronized by serum starvation
followed by serum induction (not depicted). We have pre-
viously obtained evidence for a cell cycle–regulated pro-
tein that binds to the HPV18 enhancer in S phase of the
cell cycle (33). Here, this HPV18 enhancer binding pro-
tein was purified by DNA affinity chromatography with
the use of the HPV18 enhancer fragment corresponding to
nucleotide numbers 7634–7671 (35) and termed RP3 (33).
A protein fraction eluted from the RP3 oligonucleotide
DNA affinity column with 500 mM sodium chloride was
analyzed by SDS-PAGE and 2D gel electrophoresis, and
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the amino acid sequence of the predominant polypeptide
was determined by protein microsequencing. The first 20
NH
 
2
 
-terminal amino acids as well as 5 internal peptides,
amino acids 295–309, 347–361, 410–419, 486–500, and
577–591, corresponded to predicted nucleolin residues
(40). Next, we analyzed the binding of nucleolin to the
HPV18 enhancer. Nuclear extracts of 444 cells synchro-
nized in S phase were analyzed by EMSA (Fig. 1 B) using
the labeled RP3 oligonucleotide. A retarded DNA–pro-
tein complex was detected, and this complex formation
was abolished by the addition of an Ab specific for nucleo-
lin (Fig. 1 B, lane 2). After presaturating the Ab with the
immunizing nucleolin peptide, a reappearance of retarded
nucleolin–DNA complex was observed (Fig. 1 B, lanes 3
and 4).
Next, we investigated the DNA binding activity of nu-
cleolin during the cell cycle. EMSA experiments were per-
formed with nuclear extracts of 444 cells synchronized to
the G0, G1, S, and G2 phase of the cell cycle using the la-
beled HPV18 enhancer fragment RP3 to detect nucleolin
DNA binding. Cell cycle synchronization efficiencies were
controlled as previously described (33). Fig. 1 C shows an S
phase predominance of nucleolin DNA binding (lane 3).
Similar results were obtained using cells synchronized by
serum starvation followed by serum induction (not de-
picted). Furthermore, we could demonstrate the sequence
Figure 1. S phase– and sequence-specific
binding of nucleolin to the HPV18 en-
hancer. (A) HPV18 oncogene transcription
was examined by Northern blot analysis us-
ing nuclear RNA and an E6-E7 cDNA
probe (top). S phase synchronization was
controlled by hybridization with a histone
H3 probe (bottom) and RNA concentra-
tions were verified by hybridization with a
 actin probe (middle). The differentially
spliced HPV18 early gene transcripts are in-
dicated by arrows (reference 62). (B) Nucle-
olin binds to the HPV18 enhancer. The la-
beled HPV18 enhancer oligonucleotide
RP3 and a nuclear extract from S phase syn-
chronized cells were used in EMSA. Lane 1,
S phase nuclear extract; lane 2, nucleolin Ab
was added to the DNA binding reaction;
lanes 3 and 4, nucleolin Ab was presaturated
with increasing amounts of the immunizing
peptide. Electrophoresis was performed for
90 min at 11 V/cm. (C) Cell cycle regula-
tion of nucleolin DNA binding activity.
EMSA with nuclear extracts from biochem-
ically synchronized 444 cells and the labeled
HPV18 enhancer oligonucleotide RP3.
Lane 1, G0 phase; lane 2, G1 phase; lane 3,
S phase; lane 4, G2 phase. Electrophoresis
was performed for 90 min at 11 V/cm. (D)
Sequence specificity of nucleolin binding to the HPV18 enhancer. For EMSA, a partially purified nucleolin protein fraction and labeled RP3 were used.
Partially purified nucleolin (all lanes). The binding complexes were competed by the addition of none (lane 1), 200 ng (lane 2), and 500 ng of RP3 (lane
3), and 200 ng (lane 4) and 500 ng (lane 5) of the RP3 mutant. Electrophoresis was performed for 50 min at 11 V/cm. (E) Specific interaction of nucle-
olin–GST protein with the HPV18 enhancer. Lanes 1 and 3, affinity-purified nucleolin–GST protein; lanes 2 and 4, GST protein; lanes 1 and 2, EMSA
with the labeled RP3 HPV18 enhancer oligonucleotide; lanes 3 and 4, EMSA with an unrelated AP1 recognition site. Electrophoresis was performed for
90 min at 11 V/cm.
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specificity of nucleolin binding to the HPV18 enhancer. A
deletion analysis of RP3 revealed that for nucleolin binding
the sequence motif 5
 

 
-TTGCTTGCATAA is required
(33). It was demonstrated by in vivo footprinting that the
G residues of this motif are in contact with protein on both
the sense and antisense strands in cervical cancer cells (49).
To test whether these G residues are required for nucleolin
binding, we performed EMSA competition experiments
using a RP3 mutant where the G residues of the 5
 

 
-
TTGCTTGCATAA motif were replaced by A residues in
the sense and antisense strands (Fig. 1 D). It was observed
that RP3, but not the mutant oligonucleotide, efficiently
competed with nucleolin binding to labeled RP3. It is
worthy to note that in this experiment partially purified
nucleolin was used, which explains the formation of a very
intense retarded RP3–protein complex. To additionally
demonstrate bona fide nucleolin interaction with the
HPV18 enhancer, we used a bacterially expressed, affinity-
purified nucleolin–GST fusion protein. This nucleolin–
GST protein, but not GST protein itself, bound to the en-
hancer fragment RP3 (Fig. 1 E, lanes 1 and 2) and not to
an unrelated binding site of the transcription factor AP1
(lanes 3 and 4). Thus, nucleolin is a sequence-specific and
cell cycle–regulated HPV18 enhancer binding protein.
 
Activation of HPV18 Oncogene Transcription by Nucleo-
lin.
 
To directly determine the role of nucleolin in
HPV18 oncogene transcription, we used an antisense inhi-
bition approach. We identified an effective antisense oligo-
nucleotide, as monitored by means of immunofluorescence
staining (not depicted) and immunoblotting. 444 cells
treated by the nucleolin antisense oligonucleotide showed a
strong and dose-dependent reduction of concentration of
the nucleolin protein in the nuclear extracts (Fig. 2 A, top,
lanes 2–4), whereas the nucleolin sense oligonucleotide had
no effect (lanes 5–7). 444 untreated cells were used as a ref-
erence value (Fig. 2 A, lane 1). It has been suggested that
nucleolin could be necessary for the global cellular protein
synthesis and the synthesis of ribosomal RNA (27). How-
ever, the role of nucleolin in these processes is controversial
(50). Therefore, the levels of several ubiquitous and cell cy-
cle regulatory proteins were examined after antisense inhi-
bition of nucleolin expression. We were unable to detect a
significant effect on Sp1, Cdk4, and PCNA protein levels
(Fig. 2 A, bottom panels). HPV18 oncogene transcription
in 444 cells was then analyzed by Northern blotting after
antisense inhibition of nucleolin expression (Fig. 2 B, top)
with RNA from untreated cells as a reference value (lane
1). The treatment of 444 cells with increasing amounts of
the nucleolin antisense oligonucleotide inhibited HPV18
oncogene transcription in a concentration-dependent fash-
ion (Fig. 2 B, lanes 2–4). Transcription of the 
 
 
 
actin gene
was monitored as control (Fig. 2 B, bottom). The sense oli-
gonucleotide had no effect (Fig. 2 B, top, lanes 5–7). These
results demonstrate that nucleolin activates HPV18 onco-
gene transcription.
 
Nucleolin Regulates the Chromatin Structure of the HPV18
Enhancer.
 
It has previously been shown that nucleolin in-
duces chromatin decondensation in vitro (51). In light of
Figure 2. Nucleolin controls HPV18 oncogene transcription. (A) An-
tisense inhibition of nucleolin expression. 444 cells were treated with
phosphorothioate-modified antisense or sense oligonucleotides and then
nuclear extracts were prepared. Detection of nucleolin by immunoblotting
(top). Lane 1, mock control; lanes 2–4, antisense oligonucleotide: 1 M,
5 M, and 9 M; lanes 5–7, sense oligonucleotide: 1 M, 5 M, and 9
M. The same extracts were analyzed by immunoblotting with an Ab
specific for Sp1, Cdk4, and PCNA (bottom). On the side of each immu-
noblot the positions of detected proteins are indicated by arrows. (B) Nu-
cleolin controls HPV18 oncogene expression. RNA was isolated from al-
iquots of antisense- or sense-treated cells and analyzed by Northern
blotting using an E6-E7 cDNA probe. Lane 1, untreated 444 cells; lanes
2–4, antisense oligonucleotide: 1 M, 5 M, and 9 M; lanes 5–7, sense
oligonucleotide: 1 M, 5 M, and 9 M. The differentially spliced
HPV18 mRNAs (reference 62) are indicated by arrows. The  actin con-
trol is shown at the bottom.
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our data, we considered it possible that nucleolin is in-
volved in regulating the chromatin structure of the HPV18
enhancer in vivo. Moreover, a prominent DNase I HS
site, indicative of the open chromatin structure, found in
transcriptionally active chromatin (52), has been identified
within the enhancer of HPV18 in cervical cancer cells
(47). When HPV18 enhancer chromatin structure was an-
alyzed as previously described (47) in 444 cells synchro-
nized into an S phase population, this strong DNase I HS
site was detectable (Fig. 3 A, lanes 3 and 4), whereas it was
just detected in G1 phase (not depicted). Therefore, exper-
iments in 444 cells were performed after antisense inhibi-
tion of nucleolin expression. It became evident that the
DNase I HS site in the HPV18 enhancer region was not
detected in nucleolin antisense oligonucleotide–treated
cells (Fig. 3 B, lanes 4–6) compared to sense oligonucle-
otide–treated cells (Fig. 3 B, lanes 1–3). These results show
that nucleolin is involved in opening the chromatin struc-
ture of the HPV18 enhancer and suggest that through this
mechanism, nucleolin functions as a regulator of HPV18
oncogene transcription.
 
Nucleolin as Selective Activator of HPV18 Oncogene Tran-
scription.
 
To further investigate the role of nucleolin for
HPV18 oncogene transcription, we took advantage of a
hybrid cell system consisting of the following components:
(a) HPV16
 
 
 
SiHa cells where the contiguous HPV18
URR fused to a CAT is stably integrated. In these cells the
HPV18 URR-driven CAT reporter gene is constitutively
expressed (Fig. 4 A, lane 1). We refer to these cells as
(HPV18 URR-CAT)-SiHa cells throughout the text. (b)
A SiHa 
 
 
 
HaCaT cell hybrid where the integrated HPV18
URR-CAT reporter gene is not significantly expressed
(Fig. 4 A, lane 2). We refer to these cells as (HPV18
URR-CAT)-SiHa 
 
 
 
HaCaT hybrids throughout the text.
Note that HaCaT cells are normal nontumorigenic human
keratinocytes (53). When the DNA binding activity of nu-
cleolin was investigated we found that in (HPV18 URR-
CAT)-SiHa 
 
 
 
HaCaT hybrids it was just detectable (Fig. 4
B, lane 2) whereas in (HPV18 URR-CAT)-SiHa cells sig-
nificant amounts were detected (Fig. 4 B, lane 1). At the
level of DNA sequence organization the enhancers of the
most frequent high risk HPVs, HPV18 and HPV16, are
strikingly different (18) and there is no sequence similarity
with the HPV18 enhancer fragment RP3 containing the
nucleolin binding site (5
 

 
-TTGCTTGCATAA) in the
HPV16 enhancer. To investigate whether nucleolin con-
trols the activity of the HPV16 URR, we analyzed the ex-
pression of HPV16 oncogenes in (HPV18 URR-CAT)-
SiHa and (HPV18 URR-CAT)-SiHa 
 
 
 
HaCaT hybrid
cells by Northern hybridization (Fig. 4 C). The levels of
the four HPV16 early gene transcripts (54) in both cell
types are similar (Fig. 4 C, lanes 1 and 3), demonstrating
Figure 3. Regulation of chromatin structure of the HPV18 enhancer by nucleolin. (A) HPV18 enhancer DNase I HS site mapping was performed as
previously described (reference 47). Nuclei from S phase cells were digested with DNase I: 0.25 U, 0.5 U, 1.75 U, and 2.5 U (lanes 1–4). Mock-digested
nuclei are not shown. Purified nuclear DNA was then digested with EcoR I and analyzed by Southern blotting using an E6-E7 cDNA probe for indirect
end labeling of the 3 end. The position of a DNase I HS site in the HPV18 enhancer is indicated by an arrow. (B) 444 cells were treated with 9 M nu-
cleolin sense oligonucleotide and isolated nuclei were digested with DNase I: 0.25 U, 1 U, and 1.75 U (lanes 1–3). In parallel, 444 cells were treated with
9 M antisense oligonucleotide and isolated nuclei were digested with DNase I: 0.25 U, 1 U, and 1.75 U (lanes 4–6). DNA was purified and analyzed by
Southern blotting as described in A. The mock-digested controls are not shown. The HPV18 enhancer DNase I HS site is indicated by an arrow.
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that HPV16 oncogene transcription is not affected by nu-
cleolin. To directly test the role of nucleolin in HPV18
URR regulation, we transfected (HPV18 URR-CAT)-
SiHa  HaCaT hybrid cells with a nucleolin expression
vector (46) and detected a significant induction of HPV18
URR-driven CAT reporter gene expression (Fig. 4 D,
lane 1), demonstrating a direct involvement of nucleolin in
the regulation of HPV18 oncogene transcription. Thus, in
this hybrid cell system nucleolin selectively controls
HPV18 oncogene expression.
Nucleolin Regulates Proliferation of HPV18 Cervical Cancer
Cells. It has been reported that the expression of HPV18
oncogenes leads to enhanced proliferation of HPV18 cer-
vical cancer cells (55). Therefore, we determined whether
nucleolin is required for the proliferation of these cells.
Three HPV18 cervical carcinoma cell lines and the
HPV16 carcinoma cell line SiHa were transiently treated
with nucleolin sense or antisense oligonucleotide, followed
by BrdUrd incorporation measurement. Nucleolin anti-
sense inhibition did not significantly affect the proliferation
of HPV16 SiHa cervical cancer cells (Fig. 5 A, lane SiHa).
In contrast, the proliferation rates of the three different
HPV18 cervical cancer cell lines HeLa, 444, and SW756
were strongly inhibited by antisense inactivation of nucleo-
lin (Fig. 5 A). HeLa cells were originally derived from an
adenocarcinoma and SW756 cells from a squamous cell
carcinoma of the cervix (38, 56). Immunoblotting revealed
that nucleolin protein levels were reduced to the same ex-
Figure 4. Nucleolin as selective activator of HPV18 on-
cogene transcription. (A) CAT reporter gene assay.
HPV16 SiHa cervical cancer cells containing an inte-
grated contiguous HPV18 URR fused to a CAT reporter
gene (HPV18 URR-CAT)-SiHa (lane 1; reference 39).
SiHa  HaCaT hybrid cells containing the HPV18
URR-CAT reporter gene (lane 2). HaCaT cells are nor-
mal human keratinocytes (reference 53). CAT reporter
gene activity was measured by CAT ELISA. The results
were normalized to protein concentration. (B) EMSA with
nuclear extracts from (HPV18 URR-CAT)-SiHa cells
(lane 1) and SiHa  HaCaT hybrid cells where the
HPV18 URR-CAT gene is not significantly expressed
(lane 2). The position of the retarded RP3–nucleolin com-
plex is indicated by an arrow. Conditions for EMSA are as
described in Fig. 1. (C) HPV16 oncogene transcription in
(HPV18 URR-CAT)-SiHa cells (lane 1) and SiHa 
HaCaT hybrid cells (lane 3). HaCaT cells were used as a
HPV16 control (lane 2). For Northern analysis, 0.5 g of
poly A–selected RNA was used per lane. Filters were con-
secutively hybridized with probes specific for HPV16 and
 actin. The sizes of the corresponding mRNAs are indi-
cated. (D) CAT reporter gene assay. SiHa  HaCaT hy-
brid cells containing the integrated HPV18 URR-CAT
construct were transiently transfected with a nucleolin cDNA
expression construct (lane 1; reference 46) or the empty vec-
tor (lane 2). CAT activity was measured by CAT ELISA.
The results were normalized to protein concentration.
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tent in HeLa and SiHa cells by treatment with antisense
oligonucleotide (Fig. 5 B top, lanes 2 and 5), whereas the
nucleolin sense oligonucleotide had no effect (lanes 3 and
6, respectively). Beta-actin expression was not influenced
by the antisense nor the sense oligonucleotide (Fig. 5 B,
bottom). Therefore, nucleolin selectively controls the pro-
liferation of HPV18 cancer cells in vitro.
Nucleolin Expression in HPV18 Cervical Neoplasias.
The expression pattern of nucleolin protein in human tis-
sues has not been analyzed so far. Thus, nucleolin expres-
sion in four different normal (HPV18-free) and seven
HPV18 cancerous and precancerous tissues of the cervix
uteri was examined by immunohistochemistry (Fig. 6).
Nuclear staining was seen in both squamous epithelial and
endocervical glandular cells (Fig. 6, A and C). In squa-
mous epithelium of the cervix, nucleolin expression is
found throughout except for certain superficial cells
within the stratum corneum (Fig. 6 A). In the lower basal
and parabasal layers of the squamous epithelium and in the
more differentiated cell layers, diffuse nuclear staining was
evident (Fig. 6 A). Also, glandular epithelial cells showed
diffuse nuclear staining with often more prominent stain-
ing of dot-like structures (Fig. 6 C). To evaluate the rele-
vance of our results for HPV18-associated cervical
carcinogenesis in vivo, nucleolin expression in HPV18-
associated dysplasias, invasive squamous carcinomas, and
adenocarcinomas was analyzed by immunohistochemistry.
For example, an HPV18 HSIL is shown in Fig. 6 B, and
an HPV18 adenocarcinoma is shown in Fig. 6 D. It ap-
pears that nucleolin is expressed throughout histologic
sections of the HSIL and the adenocarcinoma. A similar
staining pattern of nucleolin was seen in a total of five dif-
ferent HPV18 adenocarcinomas and two HPV18-con-
taining squamous cell carcinomas, although the latter ones
hardly revealed any nucleolar staining. Upon closer in-
spection, a difference in the distribution of nucleolin pro-
tein expression became apparent between normal and can-
cerous tissues. Whereas in the nuclei of normal squamous
and glandular epithelial cells the intranuclear nucleolin
distribution is mostly diffuse, it is speckled in the nuclei of
cancer cells and a subset of cells in HSIL (Fig. 6). Thus,
the appearance of a speckled nucleolin distribution is asso-
ciated with HPV18 cervical carcinomas. HPV DNA was
detected in tissue specimens by a published method and
typing was performed by reverse line blot hybridization
PCR (48).
Discussion
Our study reveals that the host cell protein nucleolin is a
necessary factor for HPV18 oncogene expression in cervi-
cal cancer cells and the maintenance of the proliferative
state of these cells. Hence, it is essential for the develop-
ment of HPV18-associated cervical carcinomas. Here, we
report that nucleolin binds in a sequence-specific manner
to the HPV18 enhancer and activates HPV18 oncogene
transcription in S phase of the cell cycle. Thus, we have
identified nucleolin as an S phase–specific transcription ac-
tivator. Moreover, we show that nucleolin controls the
formation of a DNase I HS site in the HPV18 enhancer.
Nuclease HS regions in chromatin reflect an open chroma-
tin structure that permits the binding of regulatory proteins
to cis acting elements in gene control regions thereby facil-
itating gene transcription (for review see reference 52). A
role for nucleolin in chromatin decondensation has been
suggested by in vitro experiments with reconstituted chro-
matin (51). Our results go beyond these in vitro data as we
demonstrate that nucleolin acts as a cell cycle stage–specific
regulator of chromatin structure in vivo.
Figure 5. Nucleolin controls proliferation of HPV18 cervical cancer
cells. (A) Proliferation rates of SiHa, HeLa, 444, and SW756 cells were
measured by means of BrdUrd incorporation after treatment with phos-
phorothioate-modified nucleolin antisense or sense oligonucleotides, and
are displayed relative to mock-treated samples. (B) Nuclear extracts of
HeLa and SiHa cells were analyzed by immunoblotting with an Ab spe-
cific for nucleolin after treatment with nucleolin sense and antisense oli-
gonucleotides. Lanes 1–3, HeLa cells; lanes 4–6, SiHa cells; lanes 1 and 3,
mock control; lanes 2 and 5, nucleolin antisense oligonucleotide; lanes 3
and 6, nucleolin sense oligonucleotide. The same extracts were analyzed
by immunoblotting with an Ab specific for  actin (bottom).
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Figure 6. Nucleolin expression in normal HPV
cervical tissue and HPV18 cervical neoplasias.
Paraffin-embedded specimens were processed for
immunohistochemistry by standard procedures us-
ing an Ab specific for nucleolin. Bound antibodies
were visualized by avidin-biotin-peroxidase-diami-
nobenzidine tetrachloride and are stained brown.
As a control, the Ab specific for nucleolin was pre-
saturated with the immunizing nucleolin peptide
(not depicted). Specimens were counterstained
with hematoxylin. The counterstained nuclei are
light blue. (A) Squamous epithelium of the human
cervix uteri. High power view of lower epithelial
cell layers is shown on the bottom right. High
power view of more superficial layers is shown on
the top right. (B) HPV18 HSIL. High power view
is shown on the right. (C) Endocervical glandular
epithelial cells. High power view is shown on the
right. (D) HPV18 adenocarcinoma of the en-
docervix. High power views of two areas are
shown on the right.
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We have previously obtained evidence for a cell cycle–
regulated protein that binds to the HPV18 enhancer in S
phase of the cell cycle and have shown that the DNA bind-
ing activity of this protein is controlled by nuclear inhibi-
tory proteins termed I-92, which form noncovalent cell cy-
cle stage–specific complexes (33). Different I-92 activities
occur in G1, G2, and G0 phase, whereas no I-92 activity is
detectable in S phase. Here, this HPV18 enhancer binding
protein was purified, sequenced, and identified as nucleo-
lin. Taken together, these results show how the regulation
of nucleolin DNA binding activity during the cell cycle is
brought about. Moreover, nucleolin has been identified as
a substrate of the cyclin-dependent kinases cdc2, cdk4, and
cdk2 (57, 58). This suggests that phosphorylation by these
cdks might be involved in controlling the complex forma-
tion of nucleolin with stage-specific I-92 inhibitors. Future
experiments will clarify this issue.
The results obtained with the (HPV18 URR-CAT)-
SiHa  HaCaT hybrid cells indicate that nucleolin does
not play a significant role in HPV16 oncogene transcrip-
tion. It was recently shown by transient transfection assays
that the HPV16 contiguous URR is inactive in HeLa cells
(59). HeLa cells are derived from an HPV18 adenocarci-
noma (56) and express considerable amounts of nucleolin
(unpublished data). Taken together, these findings illustrate
that there is a remarkable functional difference of the
HPV16 and HPV18 URRs in different cell types. These
functional differences can be explained, at least in part, by
the diverse sequence organizations of the HPV18 and
HPV16 enhancers (18, 25). In this context, it is interesting
to note that the URRs of high risk HPVs do not show se-
quence similarities with the HPV18 enhancer fragment
RP3 with the exception of HPV45, which is closely related
to HPV18 (unpublished data).
Nucleolin was originally identified as a common phos-
phoprotein of growing eukaryotic cells (27). Yet the func-
tion of nucleolin in growing cells is not completely under-
stood. Here, we have examined the relevance of nucleolin
for the proliferation of HPV18-containing cervical cancer
cells by antisense inhibition experiments. The data show
that nucleolin selectively controls the proliferation of
HPV18 cervical cancer cells by activating E6 and E7 on-
cogene transcription. As discussed above, the transcription
of the HPV16 oncogenes in (HPV18 URR-CAT)-SiHa
and (HPV18 URR-CAT)-SiHa  HaCaT hybrid cells is
not affected by the level of nucleolin DNA binding activ-
ity, and we find that the proliferation rates of these cells are
similar. Moreover, antisense inhibition of nucleolin ex-
pression in HPV16 SiHa cells did not significantly affect
cell proliferation. Based on previous speculations (28, 29),
one could think that nucleolin is essential for the global
cellular protein synthesis. Hence, nucleolin antisense inhi-
bition could theoretically block cell proliferation due to an
inhibition of global protein synthesis. Yet recent results
from the literature (50) and the results we have presented
here rule out this possibility. Moreover, a general toxicity
of the antisense oligonucleotides can be excluded by con-
trols with the sense oligonucleotide that did not affect
HPV18 oncogene expression and had no effect on general
protein expression. Transcriptional activation of the E6
and E7 oncogenes is therefore a decisive function of nu-
cleolin required for the proliferation of HPV18-infected
cervical carcinoma cells.
Cervical carcinomas develop after high risk HPV infec-
tion, although a long period of latency precedes the occur-
rence of invasive cervical cancer. It is thought that during
latency genetic alterations accumulate that ultimately lead
to high level transcription of the high risk HPV oncogenes
E6 and E7 (for review see reference 10). A continuous ex-
pression of E6 and E7 oncoproteins of HPV18 is required
for the proliferation of cervical cancer cells in vitro (60) and
in vivo (61). HPV oncogene expression is directly linked to
the development of progressive squamous epithelial neo-
plasia (17). To elucidate the role of nucleolin in cervical
carcinogenesis, we investigated nucleolin expression in
HPV18-free normal cervical tissue and in HPV18 precan-
cerous and cancerous tissues by immunohistochemistry.
This analysis revealed an alteration of the distribution of
nucleolin in cervical carcinomas. Nucleolin is homoge-
neously distributed in the nuclei of normal squamous epi-
thelial cells of the ectocervix and in glandular epithelial
cells of the endocervix. In the nuclei of HPV18 squamous
cell carcinomas and adenocarcinomas, however, the nucle-
olin distribution is speckled. Thus, nucleolin appears to be
associated with specific nuclear compartments in cervical
cancer. The identity of these nuclear structures is not clear
at this stage. One might assume that genetic alterations in
the process of tumor development could be involved in
causing this deregulation of nucleolin expression.
HPV18 infection is associated with a more aggressive
form of cervical neoplasia than HPV16 infection (8).
HPV18 has a much stronger transforming activity than
HPV16, and it was demonstrated that the URR of HPV18
is responsible for this difference (9). It is tempting to specu-
late that this difference is due to the fact that the HPV18
URR is sensitive to nucleolin activation, whereas the
HPV16 URR is not. Therefore, nucleolin might be di-
rectly linked to tumor behavior and clinical outcome. Fi-
nally, our data suggest nucleolin as a novel target molecule
for the therapy of HPV18 carcinomas of the cervix uteri.
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